Avelumab for untreated metastatic Merkel cell carcinoma

Equality Impact Assessment (Guidance development) (PDF 139 KB)

Register of interests (PDF 143 KB)

Final draft guidance

Final appraisal document (PDF 188 KB)

Committee papers (PDF 5.67 MB)

Public committee slides (PDF 1.02 MB)

Final scope (PDF 174 KB)

Final stakeholder list (PDF 188 KB)

Final appraisal document - TA517 (PDF 430 KB)

Final appraisal document - managed access agreement - TA517 (PDF 498 KB)

Committee papers (FAD) - TA517 (PDF 2.26 MB)

Public committee slides - TA517 (PDF 544 KB)

Final appraisal document - equality impact assessment - TA517 (PDF 235 KB)

Appraisal consultation document (PDF version) - TA517 (PDF 420 KB)

Committee papers (ACD) - TA517 (PDF 11.14 MB)

Public committee slides (clinical) - TA517 (PDF 423 KB)

Public committee slides (cost) - TA517 (PDF 425 KB)

Final scope - TA517 (PDF 252 KB)

Final stakeholder list - TA517 (PDF 262 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA517 (PDF 308 KB)

Equality impact assessment (Scoping) - TA517 (PDF 174 KB)